Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 32,800 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $126.69, for a total value of $4,155,432.00. Following the completion of the transaction, the chief executive officer now owns 74,131 shares of the company’s stock, valued at $9,391,656.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael A. Mussallem also recently made the following trade(s):

  • On Thursday, January 4th, Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock. The stock was sold at an average price of $114.97, for a total value of $3,771,016.00.
  • On Tuesday, December 19th, Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock. The stock was sold at an average price of $114.82, for a total value of $3,766,096.00.
  • On Monday, November 20th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock. The stock was sold at an average price of $106.86, for a total value of $3,515,694.00.

Edwards Lifesciences Corp (EW) opened at $130.21 on Thursday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $27,560.00, a P/E ratio of 45.21, a P/E/G ratio of 1.87 and a beta of 0.63. Edwards Lifesciences Corp has a 12-month low of $89.20 and a 12-month high of $138.48.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.03. The company had revenue of $888.50 million during the quarter, compared to analysts’ expectations of $868.45 million. Edwards Lifesciences had a return on equity of 27.69% and a net margin of 18.11%. Edwards Lifesciences’s quarterly revenue was up 15.7% on a year-over-year basis. During the same period last year, the business earned $0.75 earnings per share. equities analysts predict that Edwards Lifesciences Corp will post 4.49 EPS for the current year.

Edwards Lifesciences declared that its Board of Directors has authorized a stock repurchase plan on Thursday, December 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its shares are undervalued.

A number of hedge funds have recently made changes to their positions in EW. Victory Capital Management Inc. grew its holdings in Edwards Lifesciences by 4.6% in the third quarter. Victory Capital Management Inc. now owns 557,773 shares of the medical research company’s stock valued at $60,969,000 after purchasing an additional 24,399 shares during the period. Korea Investment CORP grew its holdings in Edwards Lifesciences by 144.5% in the third quarter. Korea Investment CORP now owns 355,683 shares of the medical research company’s stock valued at $38,880,000 after purchasing an additional 210,200 shares during the period. Raymond James Financial Services Advisors Inc. grew its holdings in Edwards Lifesciences by 53.3% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 11,991 shares of the medical research company’s stock valued at $1,418,000 after purchasing an additional 4,170 shares during the period. Oakbrook Investments LLC grew its holdings in Edwards Lifesciences by 25.7% in the third quarter. Oakbrook Investments LLC now owns 19,050 shares of the medical research company’s stock valued at $2,082,000 after purchasing an additional 3,900 shares during the period. Finally, ING Groep NV grew its holdings in Edwards Lifesciences by 41.2% in the third quarter. ING Groep NV now owns 22,905 shares of the medical research company’s stock valued at $2,504,000 after purchasing an additional 6,684 shares during the period. Institutional investors own 81.11% of the company’s stock.

Several brokerages have recently issued reports on EW. Cowen restated a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, February 1st. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $145.00 price objective for the company in a research note on Thursday, February 8th. SunTrust Banks restated a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, January 31st. Stifel Nicolaus restated a “buy” rating and issued a $155.00 price objective on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Finally, Guggenheim restated a “buy” rating and issued a $162.00 price objective on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Edwards Lifesciences currently has a consensus rating of “Buy” and a consensus target price of $141.15.

ILLEGAL ACTIVITY NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2018/02/15/edwards-lifesciences-corp-ew-ceo-sells-4155432-00-in-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.